Clinical Trial Detail

NCT ID NCT02819518
Title Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

triple-receptor negative breast cancer

Therapies

Paclitaxel

Pembrolizumab

nab-paclitaxel

Carboplatin + Gemcitabine

Age Groups: senior adult

Additional content available in CKB BOOST